BioSpace News Archive

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of inflammatory bowel disease during Digestive Disease Week, being held virtually May 21-23, 2021.

InspirMed Inc., a subsidiary of TLC that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine Congress.

Late-breaker is one of 20 Janssen abstracts, 16 of which show the safety profile and efficacy of STELARA in treating Crohn’s disease and ulcerative colitis at Digestive Disease Week (DDW) Virtual 2021

Hyundai Bioscience announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietary oral formulation technology, in a special issue of Pharmaceuticals.

NGM Biopharmaceuticals, Inc. will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis.

Induction therapy with Zeposia improved key symptoms of concern to patients, including rectal bleeding and stool frequency as early as Week 2 in Phase 3 True North study

Seegene Inc., a biotechnology firm specializing in molecular diagnostics has once again been recognized for its unique system for diagnosing COVID-19 variants at this year’s European Congress of Clinical Microbiology, the ECCMID.

Genesis MedTech Group, a leading medical device company, announced it has completed its Series B round, raising significant growth financing.